Announcements

April 30, 2024

Genetic Signatures (ASX:GSS) – Leadership Transition at Genetic Signatures

Dr. John Melki has stepped down from his role as CEO of the Company and from the Board of Directors.

“His scientific and executive leadership have been pivotal in enabling the Company to successfully transition from a research and development company to a commercial organisation. We sincerely thank Dr. Melki for this and wish him the very best in his future endeavours.” said Dr. Nick Samaras, Chairman.

We thank John for his leadership, dedication to Genetic Signatures’ team and investors, and for his genuine passion for improving global health.

View full announcement

April 29, 2024

Genetic Signatures (ASX:GSS) – Quarterly Activities – Appendix 4C Cash Flow Report

April 22, 2024

Genetic Signatures (ASX:GSS) – TGA authorises supply of updated Respiratory Detection Kit

March 12, 2024

Genetic Signatures (ASX:GSS) – Becoming a substantial holder

March 4, 2024

Genetic Signatures (ASX:GSS) – Change of Director’s Interest Notice

February 22, 2024

Genetic Signatures (ASX:GSS) – 1H 24 Market Update

February 22, 2024

Genetic Signatures (ASX:GSS) – Half Yearly Report and Accounts

February 1, 2024

Genetic Signatures (ASX:GSS) – Quarterly Activities and Appendix 4C

January 29, 2024

Genetic Signatures (ASX:GSS) – Change in substantial holding

January 25, 2024

Genetic Signatures (ASX:GSS) – Application for quotation of securities